Sleeve lobectomy is frequent performed to remove the complete tumor with nodal dissection.[9] There is no sufficient evidence to prove that adjuvant chemotherapy or radiotherapy is necessary for a patient with complete tumor resection.[15] The CRTCl-MAML2 fusion gene generates the CRTC1-MAML2 fusion protein.[16] This novel protein not only leads to up-regulation of the EGFR ligand amphiregulin but also contributes to tumor development by interfering with cell growth regulatory pathways.[15,17,18] The CRTC1-MAML2 fusion gene is a possible new therapeutic target for PMEC. This evidence concerns the gene MAML2 and neoplasm.